«ÉÏһƪ/Previous Article|±¾ÆÚĿ¼/Table of Contents|ÏÂһƪ/Next Article»

¡¶ÐÄÔàÔÓÖ¾¡·[ISSN:1009-7236/CN:61-1268/R]

ÆÚÊý:

2012ÄêµÚ1ÆÚ

Ò³Âë:

117-119,137

À¸Ä¿:

×ÛÊö

³ö°æÈÕÆÚ:

2012-02-25

ÎÄÕÂÐÅÏ¢/Info

Title:

Progress in treatment of myocardial infarction with transplantation of bone marrow mesenchymal stem cells

×÷Õß:

Ìï ÌÎ ×ÛÊö; Âí ±ö ÉóУ

(°ö²ºÒ½Ñ§ÔºµÚÒ»¸½ÊôÒ½ÔºÐÄÄÚ¿Æ£¬°²»Õ °ö²º 233004)

Author(s):

TIAN Tao;  MA Bin

(Department of Angiocardiology, First Affiliated Hospital, Bengbu Medical College, Bengbu 233004. Anhui, China£©

¹Ø¼ü´Ê:

¹ÇËè¼ä³äÖʸÉϸ°û; Ðļ¡¹£ËÀ; Ðļ¡ÔÙÉú

Keywords:

Bone marrow mesenchymal stem cells;  myocardial infarction;  myocardial regeneration

·ÖÀàºÅ:

R542.22

DOI:

-

ÎÄÏ×±êʶÂë:

A

ÕªÒª:

ÈÜ˨¡¢¾­Æ¤¹Ú×´¶¯Âö½éÈëÖÎÁƼ°³£¹æÒ©ÎïÖÎÁÆ¿ÉÍì¾ÈÐí¶à¼±ÐÔÐļ¡¹£ËÀ»¼ÕßµÄÉúÃü£¬µ«²»ÄÜ´Ó¸ù±¾Éϻָ´Ðļ¡Ï¸°ûÊýÁ¿¡£¹ÇËè¼ä³äÖʸÉϸ°û£¨BM-MSCS£©ÊǹÇËèÖÐÒ»ÖÖ¾ßÓжàÏò·Ö»¯Ç±ÄܵÄϸ°û£¬¿É±»ÓÕµ¼·Ö»¯ÎªÐļ¡Ñùϸ°û£¬¸ÄÉƹ£ËÀÇøµÄѪҺ¹©Ó¦¼°Ðļ¡Öع¹£¬ÎªÐļ¡¹£ËÀµÄÖÎÁÆ´øÀ´ÁËеÄÏ£Íû¡£±¾ÎľÍBM-MSCSÒÆÖ²ÖÎÁÆÐļ¡¹£ËÀµÄ·½Ê½£¬ÒÆÖ²µÄʱ»ú¼°ÁÙ´²Ó¦Óõȷ½Ãæ×÷Ò»×ÛÊö¡£

Abstract:

Although many patients with acute myocardial infarction can be saved by treatment of thrombolysis, percutaneous coronary intervention and conventional drugs, these approaches cannot restore the number of myocardial cells. Bone marrow mesenchymal stem cells (BM-MSCS) with their multidirectional differentiation potentials can be induced to differentiate into cardiomyocyte-like cells, improve circulation in the infarct area and prevent myocardium from remodeling. The manner, timing and clinic application of BM-MSCS transplantation for myocardial infarction are reviewed.

²Î¿¼ÎÄÏ×/References

[1]Âí»áÀû,¸ð¾ù²¨,Ç®¾ÕÓ¢,µÈ.¹ÇËè¸Éϸ°ûÒÆÖ²ÖÎÁÆÐļ¡¹£ËÀµÄÁÙ´²ÁÆЧ[J].ÐÄÔàÔÓÖ¾,2008,20(5):593-595.

[2]Wu Y,Zhao RC.The Role of Chemokines in Mesenchymal Stem Cell Homing to Myocardium[J].Stem Cell Rev,2011[Epub ahead of print]

[3]Ghadge SK,M¨¹hlstedt S,Ozcelik C,et al.SDF-1¦Á as a therapeutic stem cell homing factor in myocardial infarction[J].Pharmacol Ther,2011,129(1):97-108.

[4]Molina EJ,Palma J,Gupta D,et al.Improvement in hemodynamic performance,exercise capacity,inflammatory profile, and left ventricular reverse remodeling after intracoronary delivery of mesenchymal stem cells in an experimental model of pressure overload hypertrophy[J].J Thorac Cardiovasc Surg,2008,135(2):292-299.

[5]Baldazzi F,J rgensen E,Ripa RS,et al.Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route[J].Eur Heart J,2008,29(15):1819-1826.

[6]Perin EC, Silva GV,Assad JA,et al.Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction[J].J Mol Cell Cardiol,2008, 44(3):486-495.

[7]Jiang CY,Gui C,He AN,et al.Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarction[J].J Zhejiang Univ Sci B,2008,9(8):630-637.

[8]Hu X,Wang J,Chen J,et al.Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction[J].Eur J Cardiothorac Surg,2007,31(3):438-443.

[9]Wang T,Tang W,Sun S,et al.Intravenous infusion of bone marrow mesenchymal stem cells improves myocardial function in a rat model of myocardial ischemia[J].Crit Care Med,2007,35(11):2587-2593.

[10]Gao F,He T,Wang H,et al.A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats[J].Can J Cardiol,2007,23(11):891-898.

[11]Gnecchi M,Zhang Z,Ni A,et al.Paracrine mechanisms in adult stem cell signaling and therapy[J].Circ Res,2008,103(11):1204-1219.

[12]Schink the T,Bloch W,Schmidt A.In vitro secreting profile of human mesenchymal stem cells[J].Stem Cells Dev,2008,17(1):199-206.

[13]Assmus B,Rolf A,Erbs S,et al.Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction[J].Circ Heart Fail,2010,3(1):89-96.

[14]Katritsis DG,Sotiropoulou P,Giazitzoglou E,et al.Electrophysiological effects of intra- coronary transplantation of autologous mesenchymal and endothelial progenitor cells[J].Europace,2007,9(3):167-171.

[15]Williams AR,Trachtenberg B,Velazquez DL,et al.Intramyocardial stem cell injection in patients with ischemic cardiomyopathy:functional recovery and reverse remodeling[J].Circ Res,2011,108(7):792-796.

[16]Li W,Ma N,Ong LL,et al.Bcl-2 engineered MSCs inhibited apoptosis and improved heart function[J].Stem Cells,2007,25(8):2118-2127.

[17]Wang X,Zhao T,Huang W,et al.Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors[J].Stem Cells,2009,27(12):3021-3031.

[18]Zeng B,Lin G,Ren X,et al.Over-expression of HO-1 on mesenchymal stem cells promotes angiogenesis and improves myocardial function in infarcted myocardium[J].J Biomed Sci,2010,17:80.

[19]R¢island GV,Svendsen A,Torsvik A,et al.Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation[J].Cancer Res,2009,69(13):5331-5339.

[20]Íõ ·å,Ïò¶¨³É.ÆêѪ¸Éϸ°ûÒÆÖ²ÖÎÁÆÐļ¡¹£ËÀµÄÑо¿½øÕ¹[J].ÐÄÔàÔÓÖ¾,2009,21(1):119-121.

±¸×¢/Memo

±¸×¢/Memo:

ÊÕ¸åÈÕÆÚ£º2011-07-05.ͨѶ×÷ÕߣºÂí±ö£¬Ö÷ÈÎҽʦ£¬Ö÷Òª´ÓʹÚÐIJ¡µÄÑо¿ Email:mabin1965@163.com ×÷Õß¼ò½é£ºÌïÌΣ¬Ë¶Ê¿Éú Email£ºtiantaomaster@163.com

³£Óù¦ÄÜ

¸üÐÂÈÕÆÚ/Last Update: 2012-02-14